缬沙坦联合通心络胶囊对糖尿病心肌病患者血清肌钙蛋白及SOD水平的影响

目的:探讨缬沙坦联合通心络胶囊对糖尿病心肌病患者血清肌钙蛋白,SOD及生活质量的影响。方法:收集我院就诊或住院治疗的60例糖尿病心肌病患者,随机分为实验组和对照组,每组30例。对照组患者给予缬沙坦口服治疗,实验组患者在此基础上给予通心络治疗。检测并比较两组患者治疗前后血清cTnI、生活质量、SOD、运动耐量的变化情况。结果:与治疗前相比,两组患者治疗后血清cTnI和生活质量评分均下降,而SOD和运动耐量水平均升高,差异具有统计学意义(P0.05);与对照组相比,实验组患者治疗后血清cTnI和生活质量评分较低,而SOD和运动耐量水平较高,差异具有统计学意义(P0.05)。结论:缬沙坦联合通心络胶囊能够降低糖尿病心肌病患者cTnI、生活质量评分,升高其SOD以及运动耐量水平,对临床具有指导意义。     

核酸适配体生物传感器对心肌肌钙蛋白Ⅰ的检测研究

核酸适配体生物传感器是利用固定在电极表面的适配子与被测溶液中心肌肌钙蛋白Ⅰ(cTnⅠ)发生特异性结合,从而达到检测的目的.我们对玻碳电极进行阳极氧化、氨基化修饰,通过碳二亚胺盐酸盐(carbodiimide hydrochloride,EDC)、N-羟基琥珀酰亚胺(N-hydroxysuccinimide,NHS)活化作用将适配子结合在电极表面.cTnⅠ最佳检测范围是0.05~5 nmol/L,最低检测限为0.05 nmol/L,检测时间为5 min.     

Modulation of cardiac troponin C function by the cardiac-specific N-terminus of troponin I: influence of PKA phosphorylation and involvement in cardiomyopathies

The cardiac-specific N-terminus of cardiac troponin I (cTnI) is known to modulate the activity of troponin upon phosphorylation with protein kinase A (PKA) by decreasing its Ca²⁺ affinity and increasing the relaxation rate of the thin filament. The molecular details of this modulation have not been elaborated to date. We have established that the N-terminus and the switch region of cTnI bind to cNTnC [the N-domain of cardiac troponin C (cTnC)] simultaneously and that the PKA signal is transferred via the cTnI N-terminus modulating the cNTnC affinity toward cTnI_147-163 but not toward Ca²⁺. The K_d of cNTnC for cTnI_147-163 was found to be 600 μM in the presence of cTnI_1-29 and 370 μM in the presence of cTn1_1-29PP, which can explain the difference in muscle relaxation rates upon the phosphorylation with PKA in experiments with cardiac fibers. In the light of newly found mutations in cNTnC that are associated with cardiomyopathies, the important role played by the cTnI N-terminus in the development of heart disorders emerges. The mutants studied, L29Q (the N-domain of cTnC containing mutation L29Q) and E59D/D75Y (the N-domain of cTnC containing mutation E59D/D75Y), demonstrated unchanged Ca²⁺ affinity per se and in complex with the cTnI N-terminus (cTnI_1-29 and cTnI_1-29PP). The affinity of L29Q and E59D/D75Y toward cTnI_147-163 was significantly perturbed, both alone and in complex with cTnI_1-29 and cTnI_1-29PP, which is likely to be responsible for the development of malfunctions.     

芪参益气滴丸对慢性心力衰竭患者的临床疗效分析

目的:探讨芪参益气滴丸对慢性心力衰竭患者的临床疗效。方法:收集在我院就诊或住院治疗的60例慢性心力衰竭患者,随机分为实验组和对照组,每组30例,对照组患者给予贝那普利片10mg/次,1次/d;呋塞米片20mg/次,1次/d;美托洛尔缓释片23.75mg/次,1次/d;阿托伐他汀片20mg/次,1次/d;地高辛0.125mg/次,1次/d;阿司匹林肠溶片100mg/次,1次/d;单硝酸异山梨酯片20mg/次,1次/d;实验组患者在对照组基础上以及芪参益气滴丸,一次1袋,3次/d,疗程均为4周。治疗前后,对患者的血清NT-BNP、hs-CRP、cTnI水平进行检测并比较。结果:与治疗前相比,两组患者治疗后血清NT-BNP、hs-CRP、cTnI水平均显著下降(P0.05);与对照组相比,实验组患者血清NT-BNP、hs-CRP、cTnI水平较低,临床治疗总有效率较高(P0.05)。结论:芪参益气滴丸能降低慢性心力衰竭患者血清NT-BNP、hs-CRP、cTnI水平,临床疗效较好,对临床有指导意义。